IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding by Cer, R. Z. et al.
Published online 24 April 2009 Nucleic Acids Research, 2009, Vol. 37, Web Server issue W441–W445
doi:10.1093/nar/gkp253
IC50-to-Ki: a web-based tool for converting IC50
to Ki values for inhibitors of enzyme activity
and ligand binding
R. Z. Cer
1, U. Mudunuri
1, R. Stephens
1 and F. J. Lebeda
2,*
1Advanced Biomedical Computing Center, Advanced Technology Program, SAIC-Frederick Inc., NCI-Frederick,
Frederick, MD 21702, USA and
2US Army Medical Research Institute for Infectious Diseases, Fort Detrick,
MD 21702-5011, USA
Received February 6, 2009; Revised March 25, 2009; Accepted April 5, 2009
ABSTRACT
A new web-server tool estimates Ki values from
experimentally determined IC50 values for inhibitors
of enzymes and of binding reactions between
macromolecules (e.g. proteins, polynucleic acids)
and ligands. This converter was developed to
enable end users to help gauge the quality of the
underlying assumptions used in these calculations
which depend on the type of mechanism of inhibitor
action and the concentrations of the interacting
molecular species. Additional calculations are per-
formed for nonclassical, tightly bound inhibitors of
enzyme-substrate or of macromolecule-ligand sys-
tems in which free, rather than total concentrations
of the reacting species are required. Required user-
defined input values include the total enzyme (or
another target molecule) and substrate (or ligand)
concentrations, the Km of the enzyme-substrate (or
the Kd of the target-ligand) reaction, and the IC50
value. Assumptions and caveats for these calcula-
tions are discussed along with examples taken from
the literature. The host database for this converter
contains kinetic constants and other data for inhibi-
tors of the proteolytic clostridial neurotoxins (http://
botdb.abcc.ncifcrf.gov/toxin/kiConverter.jsp).
INTRODUCTION
Some analyses of networks, pathways and metagenomics
focus on identifying key proteins or polynucleic acids
as targets for inhibitory compounds. Typically, high-
throughput screening assays are initially used to compare
and down-select potential inhibitors of enzymatic activity
or macromolecule-ligand binding. Many functional assays
seek a total inhibitor concentration that reduces these
activities by 50% (IC50). However, the IC50 value depends
on concentrations of the enzyme (or target molecule),
the inhibitor, and the substrate (or ligand) along with
other experimental conditions. What is required is an accu-
rate determination of the Ki value, an intrinsic, thermo-
dynamic quantity that is independent of the substrate
(ligand) but depends on the enzyme (target) and inhibitor.
Thus, comparisons can be more readily made among dif-
ferent laboratories to characterize the inhibitors. While
these more time-consuming assays are usually done with
the most promising candidates, accurate, initial estimates
of Ki values for more of the candidates would be beneﬁcial.
A much discussed problem in the literature (1–8) is con-
verting IC50 to Ki values because even the simplest types of
inhibitory mechanisms (e.g. competitive, uncompetitive
and noncompetitive) will inﬂuence the calculation.
To help address this problem, our web-server tool cal-
culates Ki values from IC50 values using equations for
enzyme-substrate and target-ligand interactions by diﬀer-
ent inhibitory mechanisms (http://botdb.abcc.ncifcrf.gov/
toxin/kiConverter.jsp). Additional calculations are per-
formed for tightly bound inhibitors of enzyme-substrate
reactions in which free, rather than total, concentrations
of the molecular species are calculated for nonclassic
Michaelis–Menten kinetics. Similar calculations can be
performed for target molecule-ligand systems. User-
deﬁned input values include total concentrations of the
enzyme (or target molecule) and substrate (or ligand),
the Km of the enzyme-substrate (or the Kd of the target-
ligand) reaction and the IC50 value. The outputs include
tabulations of the Ki values under diﬀerent kinetic
schemes, extensive tabulations of the results, summary
histograms and the corresponding equations. Help but-
tons are available for Background, Assumptions,
Literature, Links and Equations along with examples
taken from the host database-server that contains kinetic
information on neurotoxin inhibitors. An example calcu-
lation is included here for a tight-binding inhibitor of an
enzyme–substrate reaction, while other enzyme inhibitor
and protein–ligand–inhibitor examples are also provided.
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METHODS
Reactions and equations
The website cited in (9) served as an initial design template
for our IC50-to-Ki converter. Equations (1–4) were
adapted from refs. (3), (6) and (9) whereas we derived
Equation (5) for this study. The analytic expressions for
Ki that are shown below were veriﬁed numerically by
methods used in a previous kinetic analysis (10).
The derivations for converting IC50 to Ki values pub-
lished by Brandt et al. (3) include three types of classic
inhibitor mechanisms in which diﬀerent relations may
exist between S and Km. For tightly bound inhibitors,
the equation for Ki by Copeland et al. (6) is used to take
into account the larger amounts of inhibitor bound
species, thus making the Michaelis–Menten assumption
of the total enzyme concentration being equal invalid
(5). These equations are also relevant for protein–ligand–
inhibitor (P–L–I) interactions that also adhere to the
above assumptions.
Enzyme–substrate–inhibitor reactions
For competitive inhibition
where Kd=k–1/k1 and Ki=k i/ki, the classic expression is
Ki ¼
IC50
ðS=Km þ 1Þ
if S ¼ Km, Ki ¼ IC50=2
if S >> Km, Ki << IC50
if S << Km Ki ﬃ IC50
8
<
:
1a
and for tightly bound inhibitors (5,6)
Ki ¼
ðIC50   E=2Þ
ðS=Km þ 1Þ
1b
For uncompetitive inhibition
the classic expression is:
Ki ¼
IC50
ðKm=S þ 1Þ
if S ¼ Km, Ki ¼ IC50=2
if S >> Km, Ki ﬃ IC50
if S << Km Ki << IC50
8
<
:
2a
and for tightly bound inhibitors (5,6)
Ki ¼
ðIC50   E=2Þ
ðKm=S þ 1Þ
2b
For noncompetitive inhibition (2)
where Kia=k–ia/kia and Kib=k–ib/kib, the classic expres-
sion is:
Ki ¼ IC50 when S ¼ Km or S >> Km or S << Km 3a
and for tightly bound inhibitors (5,6)
Ki ¼ IC50   E=2 3b
This noncompetitive reaction also assumes that the
inhibitor dissociation constants are equal: Kia=Kib=
Ki. Mixed inhibition, where Kia<>Kib, is not considered
here.
P–L–I reactions
For total concentrations, E is replaced by P and S is
replaced by L. Additional reaction schemes are located
at this tool’s website. As in classic enzyme–substrate
systems the relation of Ki and IC50 in competitive inhibi-
tion is:
Ki ¼
IC50
ðL=Kd þ 1Þ
4a
For protein–ligand experiments with tight-binding
inhibitors, the free rather than the total concentra-
tions of the reactants need to be used as modiﬁed from
ref. 9
Ki ¼
I50
L50
Kd þ
P0
Kd þ 1
4b
where I50 and L50 are the free concentrations of the inhib-
itor and ligand, respectively, at 50% inhibition, and P0 is
the free concentration of the protein in the absence of
inhibitor. The concentration of the free inhibitor species
is given by
I50 ¼ IC50   P0 þ PL50 1 þ
Kd
L50
  
4c
where P0=–((Kd+L–P)+[(Kd+L–P)
2+4PKd]
1/2)/2,
PL0=P–P0, PL50=PL0/2, L0=L–PL0 and L50=
L–PL50.
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for uncompetitive inhibition
Ki ¼
I50
2P0
P P0  
Kd
L50 þ 1
5
in which the variables are the same as in Equation (4)
except that L50=–((P–L)+[(P–L)
2+4(PL0Kd/2)]
1/2)/2.
Although in this study we use the term Kd to quantify
an antagonist’s eﬀect, the pharmacology-derived EC50
value is more appropriate when functional experiments
are performed (11).
General assumptions and caveats
It is assumed that all of the substrate- and inhibitor-
binding reactions are reversible and that they all have
a one-to-one stoichiometry, i.e. no multiple binding of
inhibitor molecules or any form of cooperativity, or
other complex mechanisms of inhibition such as partial
or mixed types (3). It is also assumed that in the enzymatic
reactions enzyme autocleavage did not occur and that
when substrates for ﬂuorescence resonance energy transfer
were used, appropriate corrections for inner ﬁlter eﬀects
were performed. Comparison of Km or IC50 values for a
set of inhibitor candidates is only assumed to be valid
when they are evaluated under identical experimental con-
ditions. In most experimental studies of enzyme kinetics,
the total concentrations of substrate and inhibitor used
are in excess of the enzyme concentration to make
their free and total concentrations essentially the same
(1). Under the conditions of some ligand-receptor (e.g.
protein)-binding studies, the free concentrations also
become suﬃciently important to require modiﬁcations of
these equations (1, 2), and (9).
Description of the web server
The IC50-to-Ki tool is implemented as a web resource
using an Oracle database (Oracle9i Enterprise Edition
Release 9.2.0.4.0), Java (JDK 1.5.0) and Apache web
server components including Tomcat 4.1. Information
on candidate inhibitors of the botulinum neurotoxins
was collected by mining the biomedical literature includ-
ing searches with botXminer (12) using the National
Library of Medicine’s MEDLINE/PubMed (13).
Experimental data (IC50 values) and accompanying
assay information were manually extracted from primary
literature results and other relevant databases: JCVI-
Pathema-Clostridium (13), Brenda (14) and Protein Data
Bank (15).
USAGE
An internal link to the user-accessible converter is also
located on the left side of the BotDB home page. The
four required inputs for E, S, Km and IC50 are indicated
with default settings for several examples. After submit-
ting these values by using the ‘calculate’ button, these
input data are returned along with the Ki results for the
example cases.
An illustration is provided for a tight-binding inhibitor
of an enzyme–substrate (E–S) reaction (Figure 1). The
values for this example are from data using cimoxatone,
a tight-binding inhibitor of monoamine oxidase (16). The
four inputs for E, S, Km and IC50 are 0.021, 100, 108 and
0.017, respectively, in micromolar units. The Ki results for
three modes of inhibition are returned on a new page. The
top block of results corresponds to the solutions for a
classic inhibitor (i.e. Michaelis–Menten kinetics). The
second block represents the corrections made to the ﬁrst
set of equations [Equations (1b–3b)] for tightly bound
inhibitors when there is substantial inhibitor depletion
(5,6). Equations can be viewed by clicking on a label for
a mode of inhibition. Below these two tables, histograms
plotting the six results are shown for a visual comparison.
In this example, the results from the classic and corrected
equations are quite diﬀerent. This diﬀerence in Ki values
enables the user to conclude that not all of the assump-
tions underlying classic Michaelis–Menten equations are
being obeyed and that the data are consistent with the
kinetics of a tight-binding inhibitor.
Two other examples of enzyme inhibitors are also avail-
able for users to examine at the IC50-to-Ki tool website.
For classic inhibition, data values using a candidate inhib-
itor of botulinum neurotoxin type A (17) are used as
inputs: E, S, Km and IC50 (in micromolar units) 0.0067,
300, 1300 and 3.2, respectively. In contrast to the tight-
binding inhibitor example, the returned values for Ki are
similar for classic and tight-binding kinetics indicating
that this data set is consistent with classical kinetics.
In another example of a potentially cooperative inhibi-
tor of CYP3A4 (18), the input data for E, S, Km and IC50,
in micromolar units, are 0.1, 50, 51 and 0.05, respectively.
This example returns an error message from the converter
that states that the 1:1 stoichiometry assumption may
have been violated and requests the user to enter diﬀerent
values.
Finally, Equations (4) and (5) are used to calculate Ki
values for reactions involving inhibitors of P–L-binding
reactions. For this case, a user interface similar to the
enzyme–substrate page is produced (see website). The
values for a tight-binding inhibitor of an apoptosis-related
protein from ref. 9 are used as an example calculation.
The inputs are labeled P, L, Kd and IC50. In this case,
only the competitive and uncompetitive modes of inhibi-
tion are considered. The tabulated output includes the free
concentrations of protein and ligand species in the absence
of an inhibitor (P0 and L0, respectively). The free concen-
trations at 50% inhibition are also returned for the pro-
tein, ligand, inhibitor, protein–ligand complex and P–L–I
complex (P50, L50, etc.). As with the tight-binding enzyme
inhibitor calculations, the summary histograms again indi-
cate that these data are consistent with the kinetics of a
tight-binding inhibitor.
It is our intent for this general tool to provide results
for classic and tight-binding inhibitors of enzyme activity
and ligand-binding reactions that are assumed to follow
relatively simple kinetic schemes. These diﬀerent sets of
kinetic results will allow investigators to decide whether
additional experiments are required to understand better
Nucleic AcidsResearch, 2009, Vol.37, WebServer issue W443the kinetic behaviors of their candidate inhibitors for
further research or therapeutic product development.
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Figure 1. Results page from the IC50-to-Ki web tool for a tight-binding inhibitor of monoamine oxidase. The top table contains sample input data
obtained from ref. 16. The middle table contains the results for a classic inhibitor that follows Michaelis–Menten kinetic Equations (1a–3a) for three
kinetic reactions. The bottom table contains the results for nonclassic, tight-binding inhibitor uses Equations (1b–3b) for the same three reactions.
The histograms summarize these results. Equations for each displayed mode of inhibition can be viewed by clicking on its label. A help list located
on the upper right side is available for more detailed information about this tool.
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